Boehringer Ingelheim announces the start of a Phase II clinical trial evaluating the efficacy and safety of its novel triple receptor agonist, BI 3034701,
The content in this section is supplied by for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content.
Boehringer Ingelheim announces the start of a Phase II clinical trial evaluating the efficacy and safety of its novel triple receptor agonist, BI 3034701, in people living with obesity and overweight. BI 3034701 is a potential first-in-class GLP-1/GIP/NYP2 receptor agonist designed to address obesity through three pathways, where neuropeptide Y2 -driven central control of hunger, appetite and food intake is complemented by GLP-1/GIP-mediated satiety, weight reduction, and metabolic regulation.
The novel candidate may offer a highly differentiated, complementary therapeutic option within Boehringer Ingelheim’s expanding obesity and cardiometabolic portfolio. – Boehringer Ingelheim today announces the start of a Phase II clinical trial evaluating its investigational triple GLP-1/GIP/NPY2 receptor agonist, BI 3034701, in patients with obesity and overweight. The trial represents a significant milestone for Boehringer’s cardiometabolic and obesity pipeline, which aims to address obesity as a central driver of interconnected cardiovascular, renal and metabolic conditions.
Obesity is a complex, chronic disease that impacts more than 1 in 8 people worldwide in many different ways, and can have serious long-term consequences. Due to the heterogeneity of the disease, different mechanisms are needed to address different patient needs, disease stages, and risk profiles. By engaging these three complementary biological pathways, the molecule aims to address obesity through simultaneously targeting the regulation of body weight and metabolism.
NPY2R agonism provides a potentially differentiated mechanism that is still being investigated. Based on scientific literature, activation of the NPY2 receptor modulates central hunger signaling, while its impact on broader eating behavior remains to be fully elucidated.a key factor in advancing the program into its next phase of clinical development. The Phase II study is designed to evaluate the molecule in people living with obesity and overweight, including dose finding and broader clinical evaluation of efficacy and safety.
“The obesity treatment landscape is rapidly expanding, with a need to target a broader variety of therapeutic mechanisms given that obesity is a heterogeneous disease. This approach may better enable healthcare providers to move towards matching the right treatment to the right patient at the right time,” said Dr Ania Jaestreboff MD, PhD, professor at Yale School of Medicine and Director of the Yale Obesity Research Center .
“At Boehringer Ingelheim, we are working towards a future where earlier, multi-pathway intervention leads to long-term outcomes that prevent the progression of interconnected cardiometabolic diseases,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim. “In the future, we expect obesity care to become much more differentiated, and with BI 3034701, we aim to go beyond short-term weight loss and address both the biological and behavioral drivers of obesity.
” BI 3034701 is part of a broader portfolio of therapies being developed for people living with obesity or obesity and connected metabolic health conditions, which has multiple approaches under investigation, including survodutide, a dual glucagon/GLP-1 agonist. Results from Phase III trials of survodutide were recently presented at American Diabetes Association’s 2026 Scientific Sessions. Boehringer Ingelheim’s pipeline across obesity and liver health also includes additional next-generation therapies and experimental approaches including oral treatment options.
BI 3034701 was developed in cooperation with Gubra. Boehringer Ingelheim is solely responsible for further development and global commercialization of BI 3034701. In 2016, more than 1.9 billion adults lived with overweight — defined as a body mass index of 25 or more. More than one billion people around the world are living with obesity today — and by 2030, that number could be more than double what it was in 2010.
Overweight and obesity are complex chronic conditions involving abnormal or excessive fat accumulation that present a risk to a person’s overall health. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need.
Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Clinicaltrials.gov. A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight. Available at: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association.
Circulation. 2023;148:1606–1635. doi:10.1161/CIR.0000000000001184. Bannuru, R. Introduction and Methodology: Standards of Care in Overweight and Obesity 2025. BMJ Open Diabetes Research & Care. 2025;13:e004928. doi:10.1136/bmjdrc-2025-004928. Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity.
Available at: Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial. Available at:
Please follow us on Google to support usUnited States Latest News, United States Headlines
Similar News: You can also read news stories similar to this one that we have collected from other news sources.
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.MIAMI -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole,
Read more »
Biogen's Diranersen Shows Promising Tau Reduction and Clinical Efficacy in Phase 2 Alzheimer's StudyBiogen's Phase 2 CELIA study results for diranersen, an antisense oligonucleotide targeting tau, demonstrated meaningful clinical outcomes and robust tau reduction in early Alzheimer's disease, with the 60 mg dose showing strongest response.
Read more »
US Strikes on Iranian Military Sites Ignite New Phase of Conflict, Threaten Strait of HormuzThe United States launched targeted strikes on Iranian coastal defense, missile, and maritime sites, prompting Iran to retaliate with attacks on Bahrain, Jordan, and tankers, escalating tensions and jeopardizing the critical Strait of Hormuz waterway.
Read more »
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.Strong U.S. demand and new product launches drive first-half sales in Human PharmaNet sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S.
Read more »